Skip to main content
View the latest BOT/BAL presentation from ESMO-GI

Publications

Publishing the Frontiers of Immuno-Oncology

Spotlight Publication

Botensilimab (Fc-enhanced anti-CTLA-4), Balstilimab (PD-1 inhibitor)

Emerging survival plateaus with botensilimab and balstilimab: Pan tumor data from a large phase 1b trial of advanced solid tumors

Oct 17, 2025
,
Gordon et al.
ESMO
Colorcectal
Pan Tumor
View Publication
All Molecules
This is some text inside of a div block.
All Conferences
This is some text inside of a div block.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Clinical Trials
Clear all filters
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Zalifrelimab (CTLA-4 Antagonist)

Balstilimab (anti-PD-1) in Combination with Zalifrelimab (anti-CTLA-4): Final Results from a Phase 2 Study in Patients (pts) with Recurrent/metastatic (R/M) Cervical Cancer (CC).

ESMO
European Society for Medical Oncology (ESMO) Virtual
June 2, 2022
,
O'Malley, et al.
Cervical
Read Now
Download Now
View Presentation
QS-21 STIMULON™ Adjuvant

Comparison of the Effect of Different Immunological Adjuvants on the Antibody and T Cell Response to Immunization with MUC1-KLH and GD3-KLH Conjugate Cancer Vaccines.

Other Articles & Publications
Vaccine
June 2, 2022
,
Kim, et al.
No items found.
Read Now
Download Now
View Article
QS-21 STIMULON™ Adjuvant

Saponin Adjuvant Induction of Ovalbumin-Specific CD8+ Cytotoxic T Lymphocyte Responses.

Other Articles & Publications
The Journal of Immunology
June 2, 2022
,
Newman, et al.
No items found.
Read Now
Download Now
View Article
Zalifrelimab (CTLA-4 Antagonist)

Single-agent Zalifrelimab (anti-CTLA-4) Shows Clinical Benefit in Rare Tumors – Case Reports from a Phase 2 Study (NCT02694822).

SITC
Society for Immunotherapy of Cancer (SITC)
June 2, 2022
,
Perez, et al.
No items found.
Read Now
Download Now
View Poster
Agenus Inc.
3 Forbes Road
Lexington, MA 02421-7305
T: +1 (781) 674 4400 | F: +1 (781) 674 4200
Our Science
Pipeline
Publications
Clinical Trials
Immunotherapy
About BOT + BAL
Company
Our History
Our Team
Careers
Partners
Access
Patient Access
Contact Medical Affairs
Resources
Press Releases
In the News
Patient Resources
FAQs
Investors
Investor Overview
Events
Financial Information
Opt-out preferencesCookie PolicyTerms and Conditions of UsePrivacy PolicyCommunity GuidelinesAccess to Investigational Medicines PolicyReport Adverse EventInvestor Portal
© 2025 Agenus Inc. All rights reserved.